197 related articles for article (PubMed ID: 26538432)
1. Discovery and Characterization of a Biologically Active Non-ATP-Competitive p38 MAP Kinase Inhibitor.
Wilson BA; Alam MS; Guszczynski T; Jakob M; Shenoy SR; Mitchell CA; Goncharova EI; Evans JR; Wipf P; Liu G; Ashwell JD; O'Keefe BR
J Biomol Screen; 2016 Mar; 21(3):277-89. PubMed ID: 26538432
[TBL] [Abstract][Full Text] [Related]
2. From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors.
Bauer SM; Kubiak JM; Rothbauer U; Laufer S
Methods Mol Biol; 2016; 1360():123-48. PubMed ID: 26501907
[TBL] [Abstract][Full Text] [Related]
3. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of bi-thiazole-2,2'-diamines as kinase inhibitory scaffolds.
Ngoei KR; Ng DC; Gooley PR; Fairlie DP; Stoermer MJ; Bogoyevitch MA
Biochim Biophys Acta; 2013 Jun; 1834(6):1077-88. PubMed ID: 23410953
[TBL] [Abstract][Full Text] [Related]
5. Involvement of histone H3 phosphorylation through p38 MAPK pathway activation in casticin-induced cytocidal effects against the human promyelocytic cell line HL-60.
Kikuchi H; Yuan B; Yuhara E; Takagi N; Toyoda H
Int J Oncol; 2013 Dec; 43(6):2046-56. PubMed ID: 24064676
[TBL] [Abstract][Full Text] [Related]
6. Novel strategies for inhibition of the p38 MAPK pathway.
Zhang J; Shen B; Lin A
Trends Pharmacol Sci; 2007 Jun; 28(6):286-95. PubMed ID: 17482683
[TBL] [Abstract][Full Text] [Related]
7. Kinetic mechanism for p38 MAP kinase.
LoGrasso PV; Frantz B; Rolando AM; O'Keefe SJ; Hermes JD; O'Neill EA
Biochemistry; 1997 Aug; 36(34):10422-7. PubMed ID: 9265622
[TBL] [Abstract][Full Text] [Related]
8. Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity.
Sharlow ER; Mustata Wilson G; Close D; Leimgruber S; Tandon M; Reed RB; Shun TY; Wang QJ; Wipf P; Lazo JS
PLoS One; 2011; 6(10):e25134. PubMed ID: 21998636
[TBL] [Abstract][Full Text] [Related]
9. Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases.
Schnieders MJ; Kaoud TS; Yan C; Dalby KN; Ren P
Curr Pharm Des; 2012; 18(9):1173-85. PubMed ID: 22316156
[TBL] [Abstract][Full Text] [Related]
10. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding.
Frantz B; Klatt T; Pang M; Parsons J; Rolando A; Williams H; Tocci MJ; O'Keefe SJ; O'Neill EA
Biochemistry; 1998 Sep; 37(39):13846-53. PubMed ID: 9753474
[TBL] [Abstract][Full Text] [Related]
11. Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer.
Wu J; Wei T; Tang Q; Weng B; Li W; Jiang X; Ding T; Li X; Liang G; Cai Y; Ji J
BMC Cancer; 2015 Apr; 15():276. PubMed ID: 25880284
[TBL] [Abstract][Full Text] [Related]
12. FLiK: a direct-binding assay for the identification and kinetic characterization of stabilizers of inactive kinase conformations.
Simard JR; Rauh D
Methods Enzymol; 2014; 548():147-71. PubMed ID: 25399645
[TBL] [Abstract][Full Text] [Related]
13. Designing an orally available nontoxic p38 inhibitor with a fragment-based strategy.
Guarnieri F
Methods Mol Biol; 2015; 1289():211-26. PubMed ID: 25709042
[TBL] [Abstract][Full Text] [Related]
14. Characterization and inhibition of a p38-like mitogen-activated protein kinase (MAPK) from Echinococcus multilocularis: antiparasitic activities of p38 MAPK inhibitors.
Gelmedin V; Caballero-Gamiz R; Brehm K
Biochem Pharmacol; 2008 Oct; 76(9):1068-81. PubMed ID: 18789902
[TBL] [Abstract][Full Text] [Related]
15. Extracellular nucleotides activate the p38-stress-activated protein kinase cascade in glomerular mesangial cells.
Huwiler A; Wartmann M; van den Bosch H; Pfeilschifter J
Br J Pharmacol; 2000 Feb; 129(3):612-8. PubMed ID: 10711362
[TBL] [Abstract][Full Text] [Related]
16. Kinetic mechanism and inhibitor characterization for c-jun-N-terminal kinase 3alpha1.
Ember B; Kamenecka T; LoGrasso P
Biochemistry; 2008 Mar; 47(10):3076-84. PubMed ID: 18269248
[TBL] [Abstract][Full Text] [Related]
17. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening based on pharmacophore model followed by docking simulation studies in search of potential inhibitors for p38 map kinase.
Shahlaei M; Doosti E
Biomed Pharmacother; 2016 May; 80():352-372. PubMed ID: 27133076
[TBL] [Abstract][Full Text] [Related]
19. Noradrenaline reduces the ATP-stimulated phosphorylation of p38 MAP kinase via beta-adrenergic receptors-cAMP-protein kinase A-dependent mechanism in cultured rat spinal microglia.
Morioka N; Tanabe H; Inoue A; Dohi T; Nakata Y
Neurochem Int; 2009 Sep; 55(4):226-34. PubMed ID: 19524113
[TBL] [Abstract][Full Text] [Related]
20. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
